DAWN Day One Biopharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DAWN

Price (delayed)

$17.17

Market cap

$1.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.37

Enterprise value

$1.27B

Highlights
The debt has declined by 50% year-on-year and by 21% since the previous quarter
The company's equity fell by 11% QoQ but it rose by 4.4% YoY
The quick ratio has contracted by 40% YoY and by 25% from the previous quarter
DAWN's net income is down by 33% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of DAWN
Market
Shares outstanding
87.38M
Market cap
$1.5B
Enterprise value
$1.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$188.92M
EBITDA
-$188.53M
Free cash flow
-$147.08M
Per share
EPS
-$2.37
Free cash flow per share
-$1.84
Book value per share
$3.98
Revenue per share
$0
TBVPS
$4.71
Balance sheet
Total assets
$376.05M
Total liabilities
$29.51M
Debt
$408,000
Equity
$346.54M
Working capital
$345.77M
Liquidity
Debt to equity
0
Current ratio
12.72
Quick ratio
12.42
Net debt/EBITDA
1.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48.3%
Return on equity
-51.7%
Return on invested capital
-100.1%
Return on capital employed
-54.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DAWN stock price

How has the Day One Biopharmaceuticals stock price performed over time
Intraday
-2.28%
1 week
15.08%
1 month
10.06%
1 year
20.83%
YTD
17.6%
QTD
3.93%

Financial performance

How have Day One Biopharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$206.06M
Net income
-$188.92M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 40% YoY and by 9% from the previous quarter
DAWN's net income is down by 33% year-on-year and by 8% since the previous quarter

Growth

What is Day One Biopharmaceuticals's growth rate over time

Valuation

What is Day One Biopharmaceuticals stock price valuation
P/E
N/A
P/B
4.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 9% YoY and by 3% QoQ
The stock's P/B is 49% more than its last 4 quarters average of 2.9
The company's equity fell by 11% QoQ but it rose by 4.4% YoY

Efficiency

How efficient is Day One Biopharmaceuticals business performance
The ROIC has contracted by 27% from the previous quarter but it has grown by 13% YoY
Day One Biopharmaceuticals's ROE has decreased by 22% YoY and by 7% from the previous quarter
The ROA is down by 19% year-on-year and by 6% since the previous quarter

Dividends

What is DAWN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DAWN.

Financial health

How did Day One Biopharmaceuticals financials performed over time
Day One Biopharmaceuticals's total liabilities has surged by 73% YoY and by 20% QoQ
The quick ratio has contracted by 40% YoY and by 25% from the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 50% year-on-year and by 21% since the previous quarter
The company's equity fell by 11% QoQ but it rose by 4.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.